Pharmacokinetic and toxicokinetic data must inform regulatory and development decisions with precision. This session highlights how suboptimal study design, flawed exposure profiles, and operational errors degrade data utility. We’ll explore best practices in dose selection, matrix and timepoint planning, and executional rigor — all within the context of regulatory expectations. Attendees will gain actionable insights to strengthen study design and interpretability across early-phase development.
